Compare FTCI & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | CALC |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 88.3M |
| IPO Year | 2021 | N/A |
| Metric | FTCI | CALC |
|---|---|---|
| Price | $11.87 | $6.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $11.50 | ★ $16.00 |
| AVG Volume (30 Days) | 87.4K | ★ 104.8K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,028,000.00 | N/A |
| Revenue This Year | $113.41 | N/A |
| Revenue Next Year | $106.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.53 | N/A |
| 52 Week Low | $2.13 | $1.42 |
| 52 Week High | $12.70 | $7.20 |
| Indicator | FTCI | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 58.47 | 57.37 |
| Support Level | $11.52 | $5.55 |
| Resistance Level | $12.70 | $7.20 |
| Average True Range (ATR) | 0.84 | 0.80 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 68.21 | 50.48 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.